Ahmad Doroudian, a Senior Officer and Director, acquired 375,000 Common Shares on a direct ownership basis at a price of $0.400 through a prospectus or prospectus exempt offering on October 22nd, 2018. This represents a $150,000 investment into the company's shares and an account share holdings change of 2.1%.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the
development and commercialization of therapeutic pharmaceuticals and
nutraceuticals using innovative drug delivery platform technologies.
Pivot's wholly-owned medical cannabis products division, Pivot Green
Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), conducts
research, development and commercialization of cannabinoid-based
nutraceuticals and pharmaceuticals. Pivot's wholly-owned U.S.
subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California,
will manufacture and supply finished powderized cannabis products such
as food additives, capsules, bulk powder and stick packs to the California
market. PGS has acquired "RTIC" Ready-To-Infuse Cannabis oil-to-powder
technology and Thrudermic Transdermal Nanotechnology (transdermal);
acquired worldwide rights to BiPhasixâ„¢ Dermal Drug Delivery platform
technology (topical), Solmic Solubilisation technology (oral), and
Solumerâ„¢ Oral Drug Delivery technology; and an option to acquire
worldwide rights to TriVairâ„¢ Nasal and Pulmonary Breath-Propelled Drug
Delivery Systemsâ„¢ for the delivery and commercialization of cannabinoid,
cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.Â
No Comments